Surv BioPharma

Kagoshima, Japan · Founded 2022 · Privately Held (backing)

Developer of gene therapies designed to improve the treatment of various diseases. Surv BioPharma is based in Kagoshima, Japan and was founded in 2022. Its last reported valuation was $32.5 million in Dec 2025. It has raised $21.3 million.

Last reported valuation
$32.5M
Oct 2026
Priced at
—
Total raised
$21.3M
Last round
—

Who backs Surv BioPharma?

15 investors
InvestorType
Nippon Venture CapitalVenture capital
FFG Venture Business PartnersOther
Keio Innovation InitiativeVenture capital
Kyoto University Innovation CapitalVenture capital
Sagin Capital & ConsultingVenture capital
Tokai Tokyo InvestmentOther
Fukuoka JishoOther
DCI Partners—
Fujita Innovation Capital—
Higin Capital—
+ 5 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Surv BioPharma investors

Free account
More of Surv BioPharma with a free account
  • ·The complete investor list: 15 names
  • ·Watch Surv BioPharma: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 15 firms already write checks for companies like Surv BioPharma. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View